When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Abstract: Deformable image registration is crucial for medical image analysis, yet the complexity of deep learning networks often limits their deployment on resource-limited devices. Current ...

Ohio State changed the tide of The Game and beat Michigan 27-9 to snap a four-game losing streak in the rivalry. With the return of wide receivers Carnell Tate and Jeremiah Smith from injury, Ohio ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Most startups don't die because they lack vision but because they misread early signals. Lack of demand is why 42% of startups fail, and it’s a problem that founders can spot before launch. Quibi is a ...

The trend of AI researchers developing new, small open source generative models that outperform far larger, proprietary peers continued this week with yet another staggering advancement. The goal is ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Long-Term Support release, with features ranging from structured concurrency and compact object headers to ahead-of-time method profiling and JFR CPU-time profiling on Linux, is now generally ...